华康生物医学(08622):要约人接获合共9.6万股要约股份的有效接纳

智通财经
Dec 11, 2025

智通财经APP讯,华康生物医学(08622)及要约人Anselme Limited联合公布,要约已于2025年12月11日(星期四)下午四时正截止,并无获要约人修订或延长。于2025年12月11日(星期四)下午四时正(即综合文件所载接纳要约的最后时间及日期),要约人已接获股份要约项下涉及合共9.6万股要约股份的有效接纳,占本联合公告日期本公司全部已发行股本约0.02%;及并无购股权要约项下的接纳(行使价每股0.125港元)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10